Objective: To analyze the association of the severity of the menopausal symptoms with musculoskeletal pain in Portuguese postmenopausal women.
Methods: A cross-sectional, observational study was conducted on 167 women (63.85 ± 9.36 years). The Menopause Rating Scale was used to evaluate the menopausal symptoms severity, while the Nordic Musculoskeletal Questionnaire was employed to assess the localization of the musculoskeletal pain, and multi-located pain was determined if two or more body regions were affected. Depression (Hospital Anxiety and Depression Scale), age, body mass index (BMI) and physical activity level were considered as potential confounders.
Results: A greater severity of the somato-vegetative menopausal symptoms was related to the prevention from usual activities because of pain in the neck, shoulders, elbows, wrists/hands and knees (R of Nagelkerke = 0.064, 0.043, 0.074, 0.045 and 0.045, respectively). Associations were also observed between greater age and pain in the knees, ankles and feet (R of Nagelkerke = 0.036 and 0.034, respectively), and being physically inactive with upper back pain (R of Nagelkerke = 0.060). Higher depressive symptoms were linked to pain in the hip/thighs and knees (R of Nagelkerke = 0.067 and 0.085, respectively), as well as being physically inactive was related ton in the neck (R of Nagelkerke = 0.053). Only a greater BMI was related to multi-located pain in the last 7 days (R of Nagelkerke = 0.041).
Conclusions: The findings of our study showed that, taking into account possible confounders, greater severity of the menopausal symptoms at a somatic-vegetative level was associated with more anatomical regions with musculoskeletal pain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijgo.15271 | DOI Listing |
J Extracell Vesicles
January 2025
Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Despite immense interest in biomarker applications of extracellular vesicles (EVs) from blood, our understanding of circulating EVs under physiological conditions in healthy humans remains limited. Using imaging and multiplex bead-based flow cytometry, we comprehensively quantified circulating EVs with respect to their cellular origin in a large cohort of healthy blood donors. We assessed coefficients of variations to characterize their biological variation and explored demographic, clinical, and lifestyle factors contributing to observed variation.
View Article and Find Full Text PDFJ Int Med Res
January 2025
Department of Gynecology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Uterine inversion is a rare condition that refers to the collapse of the fundus into the uterine cavity and occurs in puerperal and non-puerperal conditions. Non-puerperal uterine inversion is particularly infrequent. Diagnosing non-puerperal uterine inversion is often challenging because it resembles vaginal or cervical tumors and pelvic organ prolapse.
View Article and Find Full Text PDFJ Menopausal Med
December 2024
Department of Obstetrics and Gynaecology, Sandro Pertini Hospital, Roma, Italy.
Objectives: To compare the efficacy and safety of three different treatment options (vaginal estriol, vaginal dehydroepiandrosterone (DHEA), and ospemifene) for treating genitourinary syndrome of menopause (GSM) in breast cancer and gynecologic cancer survivors.
Methods: A retrospective comparative analysis was performed among 185 cancer survivors (including breast, endometrial, ovarian, cervical, and vulvar cancer) affected by GSM. Women were divided into three groups according to the prescribed therapy (vaginal estriol, vaginal DHEA, and ospemifene).
J Menopausal Med
December 2024
Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
This study investigated the impact of menopause on the progression and management of common benign gynecological conditions such as polycystic ovary syndrome, endometriosis, uterine fibroids, and adenomyosis. These conditions often present with menstruation-related symptoms such as irregular cycles, heavy bleeding, and pelvic pain. While these symptoms typically subside after menopause, the underlying pathology of such benign gynecological conditions may be differentially affected by the physiological changes associated with menopause, sometimes leading to exacerbation or additional management challenges.
View Article and Find Full Text PDFClin Breast Cancer
December 2024
Sermonix Pharmaceuticals, Columbus, OH.
Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.
Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!